BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32536993)

  • 1. Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation.
    Liang H; Cui Y; Bu H; Liu H; Yan P; Cui L; Chen L
    Exp Ther Med; 2020 Jul; 20(1):211-218. PubMed ID: 32536993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.
    Wu XA; Xie G; Li XQ; Wu HT; Wang X
    Clin Chim Acta; 2018 Apr; 479():20-24. PubMed ID: 29305846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of interleukin-6-572C/G promoter polymorphism and serum levels to post-percutaneous coronary intervention restenosis.
    Gao J; Liu Y; Cui RZ; Mao YM; Zhou J; Chen Q; Zhao FM; Yang GM
    Chin Med J (Engl); 2013 Mar; 126(6):1019-25. PubMed ID: 23506572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of peripheral blood eosinophil count in predicting in-stent restenosis in patients with stable angina pectoris undergoing drug eluting stenting.
    Hajizadeh R; Ghaffari S; Separham A; Shokouhi B; Kavandi H; Pourafkari L; Nader ND
    Rom J Intern Med; 2017 Dec; 55(4):229-236. PubMed ID: 28672766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.
    Yi M; Tang WH; Xu S; Ke X; Liu Q
    Front Cardiovasc Med; 2022; 9():837330. PubMed ID: 35669469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent.
    Wang JL; Qin Z; Wang ZJ; Shi DM; Liu YY; Zhao YX; Yang LX; Cheng WJ; Zhou YJ
    J Geriatr Cardiol; 2018 Feb; 15(2):137-145. PubMed ID: 29662507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is a bare-metal stent still useful for improving the outcome of percutaneous coronary intervention? From the FU-Registry.
    Gondo K; Ike A; Ogawa M; Shirai K; Sugihara M; Nishikawa H; Iwata A; Kawamura A; Mori K; Zhang B; Miura S; Yasunaga S; Saku K
    J Cardiol; 2017 Apr; 69(4):652-659. PubMed ID: 27492658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHA
    Zhao SG; Xu JJ; Tao ZH; Jin L; Liu Q; Zheng WY; Jiang LQ; Wang NF
    J Int Med Res; 2019 Jun; 47(6):2533-2544. PubMed ID: 31039653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of miR-143 and miR-145 are associated with coronary in-stent restenosis within 1 year of follow-up after drug-eluting stent implantation.
    Yuan Y; Liu X; Hao S; He Q; Shen Z
    Ann Transl Med; 2020 Jun; 8(12):756. PubMed ID: 32647681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis.
    Wang X; Lu W; Wang X; Pan L; Fu W; Liu Q; Han Z; Sun G; Qin X; Li R; Zheng X; Shan Y; Qiu C
    Int J Cardiovasc Imaging; 2020 Feb; 36(2):171-178. PubMed ID: 31919705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remnant Lipoprotein Cholesterol Independently Associates With In-Stent Restenosis After Drug-Eluting Stenting for Coronary Artery Disease.
    Xu X; Pandit RU; Han L; Li Y; Guo X
    Angiology; 2019 Oct; 70(9):853-859. PubMed ID: 31167539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study.
    Lin XL; Li QY; Zhao DH; Liu JH; Fan Q
    Front Cardiovasc Med; 2022; 9():943185. PubMed ID: 36237913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictors of in-stent restenosis in coronary heart disease patients complicating with diabetes mellitus within 2 years after drug-eluting stents implantation].
    Chen J; Chen Y; Tian F; Han Y; Jing J; Liu J; Wang J; Zhou S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Jan; 42(1):14-8. PubMed ID: 24680263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The predictive value of epicardial adipose tissue and inflammatory factors for in-stent restenosis].
    Zhou QN; Lin WH; Jing R; Liu JJ; Shi HY; Yang RF; Gao P; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(47):3732-3736. PubMed ID: 31874499
    [No Abstract]   [Full Text] [Related]  

  • 19. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.